Sign up online today & collaborate
or click here to find out more
Patients with ulcerative colitis will get treatment with Takeda’s biologic Entyvio on the National Health Service in England and Wales, after cost regulators issued final guidance on its use.
According to National Institute for Health and Care Excellence guidelines, Enyvio (vedolizumab) should be considered for adults with moderate-to-severe UC when conventional therapy or TNF-alpha inhibitors doesn’t work or can’t be tolerated.
For more click here
Source: Pharma Times